Privia Health Group (PRVA) Q2 2025 earnings summary

Executive summary

• Achieved strong execution and double-digit growth in key metrics for Q2 and first half of 2025, including implemented providers up 13.8% and practice collections up 18.5% year-over-year.

• Raised full-year 2025 guidance above prior high end for practice collections, GAAP revenue, platform contribution, and adjusted EBITDA.

• Business model features stable, recurring earnings, diversified contracts, and robust free cash flow generation.

• Entered Arizona market with $95 million IMS transaction, ending Q2 with $390.1 million in cash and no debt.

• Consistent growth and profitability demonstrated over multiple years, with expectations for continued compounding growth.

Financial highlights

• Q2 2025 revenue grew 23.4% year-over-year to $521.2 million; six-month revenue reached $1.00 billion, up 19.5%.

• Practice collections for Q2 were $862.9 million, up 18.5% year-over-year; first half collections totaled $1.66 billion, up 15.7%.

• Adjusted EBITDA for Q2 was $29.0 million, up 31.6% year-over-year; six-month adjusted EBITDA was $55.9 million, up 33.3%.

• Adjusted EBITDA margin for Q2 was 25.2%, up from 22.1% in Q2 2024.

• Ended Q2 with $390.1 million in cash and no debt.

Outlook and guidance

• FY 2025 guidance raised above prior high end: practice collections above $3,250 million, GAAP revenue above $1,900 million, platform contribution above $218 million, and adjusted EBITDA above $110 million.

• At least 80% of full-year adjusted EBITDA expected to convert to free cash flow due to capital-light model.

• Guidance includes Arizona market entry and assumes no further business development activity.

• Expect to end 2025 with more than $450 million in cash, assuming no further capital deployment.

• De minimis capital expenditures anticipated for full-year 2025.